All In Biotech

Drug Trial Radar · NCT07752121

First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms

A Prospective, Multicenter, Non-Interventional Study Assessing First-line Luspatercept in Anemic Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Neoplasms Requiring Red Blood Cell Transfusions

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

190

Planned (sponsor's estimate)

Start

Sep 3, 2026

Primary completion

Aug 31, 2030

Study completion Aug 31, 2030

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 7, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will observe adults with lower-risk myelodysplastic neoplasms (MDS) who have anemia requiring regular red blood cell transfusions and who are prescribed first-line luspatercept as part of routine medical care. The study will follow participants for up to 2 years to understand how often treatment leads to periods without transfusions, changes in hemoglobin levels, health-related quality of life, and safety outcomes. Information on treatment use and outcomes in routine clinical practice in Germany will also be collected.

Conditions

  • Myelodysplastic Neoplasms

Interventions

  • LuspaterceptDrug

    As per product label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants achieving red blood cell transfusion independence (RBC-TI) for at least 8 consecutive weeksTime frame: Up to Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Universitätsmedizin Johannes Gutenberg Universität Mainz

    Mainz, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.